The Effect of 3-Month Growth Hormone Administration and 12-Month Follow-Up Duration among Heart Failure Patients Four Weeks after Myocardial Infarction: A Randomized Double-Blinded Clinical Trial

Table 2

Distribution of clinical cardiovascular outcomes at baseline, 3, and 12 months after study initiation across different categories of intervention or control group.

Endpoint	GH group ()				^†	^‡	Placebo group ()				^†	^‡	^¶	^ƪ	^ƛ
	Baseline	After 3 months	After 12 months				Baseline	After 3 months	After 12 months
LVEF (%)				0.002	0.008	0.95				0.25	0.05	0.02	0.95	0.003	0.06
IVS thickness (mm)				0.70	0.10	0.06				0.10	0.05	0.42	0.07	0.28	0.55
Posterior LV wall thickness (mm)				0.37	0.47	0.38				0.99	0.18	0.18	0.62	0.82	0.78
End diastolic diameter (mm)				0.44	0.21	0.76				0.77	0.55	0.34	0.53	0.43	0.76
End systolic diameter (mm)				0.78	0.56	0.44				0.23	0.39	0.60	0.76	0.03	0.32
Pulmonary arterial pressure (mmHg)				0.32	0.85	0.22				0.46	0.77	0.55	0.50	0.81	0.51

GH: growth hormone; LVEF: left ventricular ejection fraction; IVS: interventricular septum; LV: left ventricle. value between baseline and after 3 months. ^† value between after 3 months and after 12 months. ^‡ value between baseline and after 12 months. ^¶ value between growth hormone and placebo groups at baseline. ^ƪ value between growth hormone and placebo groups after 3 months. ^ƛ value between growth hormone and placebo groups after 12 months.